Navigation Links
Ikaria® Appoints Chief Medical Officer
Date:4/11/2012

HAMPTON, N.J., April 11, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that Joseph Stauffer, D.O., has been appointed Chief Medical Officer.  In this role, Dr. Stauffer will be responsible for all medical, patient safety, risk management, and regulatory activities related to Ikaria's commercialized product, INOMAX® (nitric oxide) for inhalation, as well as future launch products.

"We are delighted to welcome Joe, whose extensive medical leadership experience will be of great benefit to the many aspects of our unique INOMAX offering," commented Daniel Tasse, Chairman and CEO of Ikaria. "We believe his previous experience in pharmaceuticals and at the FDA provide him with a unique opportunity to view our products with an exquisite balance of medical insight, business acumen and regulatory compliance."

Dr. Stauffer most recently held the position of Chief Medical Officer at PharmacoFore, a California-based biopharmaceutical company.  Prior to that, he was Chief Medical Officer at DURECT Corporation, a specialty pharmaceutical company, and at Alpharma/King Pharmaceuticals.  He began his pharmaceutical career at Abbott Laboratories in 2002, where he was global medical director for its pain portfolio.  Dr. Stauffer also served as a medical officer in the Analgesic Division of the FDA's Center for Drug Evaluation and Research from 2000-2002, where he reviewed Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for opiate, non-opiate, anti-inflammatory and novel pain compounds.  He graduated from the Philadelphia College of Osteopathic Medicine and completed residency training in Anesthesiology at the Johns Hopkins University Hospital where he is currently an Adjunct Assistant Professor in the Department of Anesthesiology and Critical Care Medicine. Additionally, he completed hi
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
2. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
3. Ikaria® to Present at 2011 BIO Investor Forum
4. Ikaria® To Present at 2011 BIO Business Forum and International Convention
5. Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research
6. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
7. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
8. InspireMD Appoints Dr. James Barry to Its Board of Directors
9. Veracyte Appoints Mark Spring as Chief Financial Officer
10. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
11. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... to Host Conference Call at 12:30 p.m. Eastern Time, September 19, ... ... Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that ... obtained the,United States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with,Allergan,s ...
... Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company ... M.D., has been appointed,President and Chief Executive Officer, ... remain with the Company through the end,of 2007, ... on CuraGen,s,Board of Directors until the Annual Stockholders ...
... for ... inflammatory bowel disease., OKLAHOMA CITY, Sept. 18 Altheus Therapeutics, ... trials,testing the efficacy of its therapy for the treatment of inflammatory ... by the,Oklahoma Seed Capital Fund and Oklahoma Equity Partners. About ...
Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 2CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 3CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 4CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer 5Altheus Therapeutics Secures $3.6 Million in Venture Capital 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... A major step in commercializing the groundbreaking research ... University of Minnesota signed an exclusive, global license agreement ... worldwide attention in 2008 when her team announced that ... laboratory. The technology licensed to Miromatrix holds the ...
... Calif., Feb. 16, 2010 Butterfly experts have suspected for ... in explaining wing color diversity. Now, for the first time, ... at least in nine Heliconius species. ... ultraviolet colors also have UV-yellow pigment on their wings, reports ...
... coastal fog has decreased significantly over the past 100 years, ... according to a new study by University of California, Berkeley, ... a natural cycle of the result of human activity, but ... entire redwood ecosystem, the scientists say. , "Since 1901, the ...
Cached Biology News:U of Minnesota finalizes license agreement to form start-up company based on Doris Taylor research 2Butterfly vision, wing colors linked, UCI study finds 2Fog has declined in past century along California's redwood coast 2Fog has declined in past century along California's redwood coast 3Fog has declined in past century along California's redwood coast 4